As shown by Pilotte et al., TDO inhibition through a novel synthetic inhibitor was able to restore the ability of mice to reject TDO-expressing tumors in a preclinical mastocytoma model (Pilotte et al., 2012). This evidence concerns the gene TDO2 and mastocytoma.